Zealand to present at two international healthcare investor conferences in June 2017
(Thomson Reuters ONE) -
Press Release - No. 4 / 2017
Zealand to present at two international healthcare investor conferences in June
2017
Copenhagen, June 2, 2017 - Zealand announces that its President and CEO, Britt
Meelby Jensen, and Executive Vice President and CFO, Mats Blom, will present the
Company and host investor meetings at the following healthcare investor forums
taking place in New York and London in June 2017.
Jefferies 2017 Healthcare Conference, New York - June 6-7, 2017
Zealand Pharma A/S is presenting on: Tue, Jun 6 at 4:30-4:55 PM in 5 Ballroom
(breakout at 5:00 PM-05:25 PM in Alvin Room). Britt Meelby Jensen, President and
CEO and Mats Blom, Executive Vice President and CFO, will represent the Company.
Citi 2016 Global Healthcare Conference, London - June 21, 2017
Zealand will host one-on-one investor meetings. Britt Meelby Jensen, President
and CEO will represent the Company.
Please note that no new financial or other material information relating to
Zealand and its business will be disclosed at these meetings.
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj(at)zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl(at)zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery, design and development of innovative peptide-
based medicines. Zealand has a portfolio of medicines and product candidates
under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and
a pipeline of internal product candidates focusing on specialty gastrointestinal
and metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi.
Lixisenatide is marketed as Adlyxin(®) in the U.S. and as Lyxumia(®) in the rest
of the world. Lixisenatide has been developed in a combination with basal
insulin glargine (Lantus(®)) and is marketed as Soliqua(®) 100/33 in the U.S.
and has been approved as Suliqua(®) in Europe and launched in the Netherlands.
Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue
treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for
short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version)
intended for use in a dual-hormone artificial pancreas system to reduce the risk
of hypoglycemia and better diabetes management (Phase 2) and other earlier-stage
clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information
about the Company's business and activities, please visit www.zealandpharma.com
or follow Zealand on Twitter (at)ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names
(pINN).
4-17_0602 Investor conferences:
http://hugin.info/136974/R/2110078/801896.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.06.2017 - 09:26 Uhr
Sprache: Deutsch
News-ID 545993
Anzahl Zeichen: 3818
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Zealand to present at two international healthcare investor conferences in June 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Zealand Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
